Christoph Kuppe

Christoph Kuppe

Top Cited Scholar 2026
Auto-generated profile, based on publicly available information

Christoph Kuppe

Division of Nephrology and Clinical Immunology, RWTH Aachen University, Medical Faculty, Aachen, Germany

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 August 2022 in Nature
Verified
Journal Article
Closed access
PDF file
CKChristoph Kuppe
Christoph Kuppe
RFRicardo O. Ramirez Flores
Ricardo O. Ramirez Flores
ZLZhijian Li
Zhijian Li
SHSikander Hayat
Sikander Hayat
RLRebecca T. Levinson
Rebecca T. Levinson
RKRafael Kramann
Rafael Kramann

11 November 2020 in Nature
Verified
Journal Article
Closed access
PDF file
CKChristoph Kuppe
Christoph Kuppe
MIMahmoud M. Ibrahim
Mahmoud M. Ibrahim
JKJennifer Kranz
Jennifer Kranz
XZXiaoting Zhang
Xiaoting Zhang
SZSusanne Ziegler
Susanne Ziegler
RKRafael Kramann
Rafael Kramann

8 March 2024 in Nature Biotechnology
Verified
Journal Article
Open access
PDF file
FRFeng Ren
Feng Ren
AAAlex Aliper
Alex Aliper
JCJian Chen
Jian Chen
HZHeng Zhao
Heng Zhao
SRSujata Rao
Sujata Rao
AZAlex Zhavoronkov
Alex Zhavoronkov
Idiopathic pulmonary fibrosis (IPF) is an aggressive interstitial lung disease with a high mortality rate. Putative drug targets in IPF have failed to translate into effective therapies at the clinical level. We identify TRAF2- and NCK-interacting kinase (TNIK) as an anti-fibrotic target using a predictive artificial intelligence (AI) approach. Using AI-driven methodology, we generated INS018_055, a small-molecule TNIK inhibitor, which exhibits desirable drug-like properties and anti-fibrotic activity across different organs in vivo through oral, inhaled or topical administration. INS018_055 possesses anti-inflammatory effects in addition to its anti-fibrotic profile, validated in multiple in vivo studies. Its safety and tolerability as well as pharmacokinetics were validated in a randomized, double-blinded, placebo-controlled phase I clinical trial (NCT05154240) involving 78 healthy participants. A separate phase I trial in China, CTR20221542, also demonstrated comparable safety and pharmacokinetic profiles. This work was completed in roughly 18 months from target discovery to preclinical candidate nomination and demonstrates the capabilities of our generative AI-driven drug-discovery pipeline.

23 October 2024 in Nature
Verified
Journal Article
Closed access
PDF file
JAJunedh M. Amrute
Junedh M. Amrute
XLXin Luo
Xin Luo
VPVinay Penna
Vinay Penna
SYSteven Yang
Steven Yang
TYTracy Yamawaki
Tracy Yamawaki
KLKORY J. LAVINE
KORY J. LAVINE

1 November 2016 in Cell Stem Cell
Verified
Journal Article
Closed access
RKRafael Kramann
Rafael Kramann
CGClaudia Goettsch
Claudia Goettsch
JWJanewit Wongboonsin
Janewit Wongboonsin
HIHiroshi Iwata
Hiroshi Iwata
RSRebekka K. Schneider
Rebekka K. Schneider
BHBenjamin D. Humphreys
Benjamin D. Humphreys

1 February 2022 in Cell Stem Cell
Verified
Journal Article
Open access
JJJitske Jansen
Jitske Jansen
KRKatharina C. Reimer
Katharina C. Reimer
JNJames S. Nagai
James S. Nagai
FVFinny S. Varghese
Finny S. Varghese
GOGijs Overheul
Gijs Overheul
RKRafael Kramann
Rafael Kramann
Kidney failure is frequently observed during and after COVID-19, but it remains elusive whether this is a direct effect of the virus. Here, we report that SARS-CoV-2 directly infects kidney cells and is associated with increased tubule-interstitial kidney fibrosis in patient autopsy samples. To study direct effects of the virus on the kidney independent of systemic effects of COVID-19, we infected human-induced pluripotent stem-cell-derived kidney organoids with SARS-CoV-2. Single-cell RNA sequencing indicated injury and dedifferentiation of infected cells with activation of profibrotic signaling pathways. Importantly, SARS-CoV-2 infection also led to increased collagen 1 protein expression in organoids. A SARS-CoV-2 protease inhibitor was able to ameliorate the infection of kidney cells by SARS-CoV-2. Our results suggest that SARS-CoV-2 can directly infect kidney cells and induce cell injury with subsequent fibrosis. These data could explain both acute kidney injury in COVID-19 patients and the development of chronic kidney disease in long COVID.